Search bioRxiv⌕ Search

Biology subjects

Kuypers, K. P. C.

Publications and source records attributed to Kuypers, K. P. C..

2 recordsLinked to original sources

Psilocybin acutely dissociates cognitive and affective empathy, with empathic concern predicting persisting positive psychological effects

BackgroundPsychedelics have been proposed to enhance empathy and social connectedness, but it remains unclear whether these effects reflect global increases in empathic ability, whether they persist beyond the acute drug state, and whether they contribute to later psychological outcomes. MethodsIn a randomized, double-blind, placebo-controlled, parallel-group study, healthy participants received psilocybin (0.17 mg/kg) or placebo. Three dissociable components of empathy were assessed using the Multifaceted Empathy Test at baseline, during the acute drug state, and 7 days later: cognitive empathy (accuracy of emotion identification), emotional arousal (affective activation in response to anothers emotional state) and empathic concern (other-oriented compassion toward the depicted person. Persisting positive psychological effects were assessed at follow-up. Circulating oxytocin was measured, and spectral dynamic causal modeling was applied to resting-state fMRI data acquired during the acute drug state to examine effective connectivity within an empathy-relevant network. ResultsCompared with placebo, psilocybin acutely reduced cognitive empathy selectively for positive stimuli, while increasing emotional arousal for positive stimuli and empathic concern across valences. These empathy-related effects did not persist 7 days later. However, acute increases in empathic concern mediated later positive psychological changes, including improved attitudes about life and self, mood, and relationships. Psilocybin also increased circulating oxytocin compared to baseline, but oxytocin changes were not associated with empathy changes. Effective-connectivity analyses showed that empathic responding under psilocybin was associated with altered directional coupling among superior temporal and parahippocampal regions. ConclusionsPsilocybin does not simply enhance empathy, rather it impairs the identification of positive emotional states while heightening affective engagement and concern. Although these effects do not persist, acute empathic concern may contribute to later positive psychological change.

neuroscience↗

Sex Differences in Acute Responses to Psychedelics: Evidence for Greater Subjective Intensity and Impairment in Female Participants

Serotonergic psychedelics are advancing as psychiatric treatments, yet acute responses vary between individuals and the contribution of sex, a fundamental biological variable, remains largely unexamined. We pooled two double-blind, placebo-controlled randomized studies in healthy volunteers (N = 94 drug observations; 43 male, 51 female) comparing psilocybin 15 mg, 2C-B 20 mg, and LSD 50 ug. Linear mixed models tested sex differences in acute subjective effects (visual analogue scales), retrospective altered-states ratings (5D- and 11-ASC), empathy (Multifaceted Empathy Test), and peak (Cmax) and total (AUC) drug exposure, with treatment and sex as fixed factors and age as a covariate. Female participants reported numerically higher subjective ratings than male participants on most measures. After adjustment for age, sex differences were significant on five measures, most robustly for feeling under the drugs influence, reduced vigilance, and impaired control and cognition, with medium-to-large effects. These effects were largely consistent across the three drugs. No sex differences emerged on any empathy measure or in peak drug concentrations, indicating that female's stronger responses occurred at equivalent drug exposure. Female participants may experience more intense acute subjective effects and greater perceived impairment under psychedelics, independent of age and not explained by drug exposure. These preliminary findings, implicating pharmacodynamic rather than pharmacokinetic mechanisms, have implications for dosing, informed consent, and safety monitoring, and underscore the need to treat sex as a biological variable in adequately powered psychedelic trials.

neuroscience↗